Processa Pharmaceuticals, Inc.
PCSA
$0.2292
$0.01125.14%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.00% | -21.70% | -6.55% | 46.95% | 60.17% |
| Total Depreciation and Amortization | 175.00% | 200.00% | 250.00% | -99.75% | -99.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.34% | -19.73% | -70.78% | -93.33% | -94.75% |
| Change in Net Operating Assets | 760.73% | -187.11% | -118.57% | -150.42% | -41.35% |
| Cash from Operations | -16.93% | -49.11% | -39.46% | -31.82% | 3.84% |
| Capital Expenditure | -14.29% | -14.29% | -14.29% | -14.29% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -14.29% | -14.29% | -14.29% | -14.29% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -147.83% | -544.44% | -- | -- | -- |
| Issuance of Common Stock | 94.82% | -5.78% | 22.21% | 13.56% | -1.10% |
| Repurchase of Common Stock | 86.13% | 92.73% | 70.59% | 61.27% | -16.89% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 97.84% | -4.43% | 23.36% | 14.56% | -1.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 143.96% | -230.71% | -95.54% | -80.91% | 8.30% |